Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund grew its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 14.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 614,981 shares of the biopharmaceutical company's stock after purchasing an additional 75,592 shares during the period. Bristol-Myers Squibb comprises about 0.5% of Illinois Municipal Retirement Fund's portfolio, making the stock its 20th biggest position. Illinois Municipal Retirement Fund's holdings in Bristol-Myers Squibb were worth $31,555,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in BMY. OFI Invest Asset Management purchased a new position in Bristol-Myers Squibb in the third quarter worth approximately $25,000. Milestone Investment Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb during the 3rd quarter worth $27,000. Blue Bell Private Wealth Management LLC grew its stake in shares of Bristol-Myers Squibb by 61.5% during the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 200 shares in the last quarter. Legacy Financial Group LLC purchased a new position in Bristol-Myers Squibb in the third quarter valued at $39,000. Finally, Turtle Creek Wealth Advisors LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at $40,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock traded up $0.21 during trading hours on Monday, reaching $49.14. 7,909,875 shares of the company's stock were exchanged, compared to its average volume of 15,608,706. The company has a market cap of $99.59 billion, a P/E ratio of 12.73, a price-to-earnings-growth ratio of 1.48 and a beta of 0.39. Bristol-Myers Squibb has a 1 year low of $47.58 and a 1 year high of $70.93. The company's 50 day moving average is $51.22 and its two-hundred day moving average is $51.38. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, topping analysts' consensus estimates of $1.55 by $0.15. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The company had revenue of $11.48 billion for the quarter, compared to the consensus estimate of $11.19 billion. During the same period in the previous year, the business earned $1.82 earnings per share. Bristol-Myers Squibb's quarterly revenue was up .6% compared to the same quarter last year. Equities research analysts anticipate that Bristol-Myers Squibb will post 6.63 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.88%. Bristol-Myers Squibb's dividend payout ratio is currently 62.18%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on BMY shares. StockNews.com lowered Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Monday, April 15th. William Blair restated a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Bank of America lowered shares of Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and cut their price target for the stock from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Redburn Atlantic downgraded shares of Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. Finally, Societe Generale cut Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a research report on Monday, March 11th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $61.18.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.